Ju Ji-Hyeon, Cho Mi-La, Jhun Joo-Youn, Park Min-Jung, Oh Hye-Joa, Min So-Youn, Cho Young-Gyu, Hwang Seu-Yun, Kwok Seung-Ki, Seo Soo-Hong, Yoon Chong-Hyeon, Park Sung-Hwan, Kim Ho-Youn
The Center for Rheumatic Diseases in Kangnam St. Mary's Hospital and Rheumatism Research Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Immunol Lett. 2008 Apr 15;117(1):16-25. doi: 10.1016/j.imlet.2007.09.011. Epub 2007 Oct 22.
The receptor activator of nuclear factor kappaB ligand (RANKL) is an osteoclastogenic mediator, which is mainly expressed by stromal cells and osteoblast. However, T cells can also be an important provider for RANKL in special condition such as autoimmune arthritis. We examined the RANKL expression of hyporesponsive CD4+ T cells induced by oral feeding with type II collagen in collagen-induced arthritis (CIA) mice. The potential of RANKL expression in CD4+ T cells was downregulated in tolerance, as compared with CIA. One of possible explanations for this phenomenon is that CII-specific T cell activation was intrinsically impaired in oral tolerance, which caused suppression of RANKL expression of CD4+ T cells. We also investigated the extrinsic role of cytokine in this process. IL-17, well-known pro-inflammatory cytokine was upregulated in CIA and downregulated in tolerance. IL-17 had a potential to stimulate T cells to express RANKL in dose-dependent manner. IL-17-associated RANKL expression of CD4+ T cells was downregulated in oral tolerance, suggesting that the induction of tolerance ameliorates IL-17-induced RANKL expression of T cells in murine CIA. We also discovered that CIA - T cells could enhance osteoclastogenesis but not oral tolerance - T cells. Oral tolerance might be promising therapeutic option in viewpoints of modulating autoreactivity of CII which can induce not only IL-17 production but also RANKL expression in CD4+ T cells.
核因子κB受体活化因子配体(RANKL)是一种破骨细胞生成介质,主要由基质细胞和成骨细胞表达。然而,在自身免疫性关节炎等特殊情况下,T细胞也可能是RANKL的重要来源。我们检测了胶原诱导性关节炎(CIA)小鼠经口服II型胶原诱导的低反应性CD4+ T细胞中RANKL的表达。与CIA相比,CD4+ T细胞中RANKL表达的潜能在耐受性状态下被下调。对此现象的一种可能解释是,口服耐受性中CII特异性T细胞活化存在内在缺陷,导致CD4+ T细胞RANKL表达受到抑制。我们还研究了细胞因子在此过程中的外在作用。众所周知的促炎细胞因子IL-17在CIA中上调,在耐受性状态下下调。IL-17具有以剂量依赖方式刺激T细胞表达RANKL的潜能。在口服耐受性中,CD4+ T细胞与IL-17相关的RANKL表达下调,这表明在小鼠CIA中,耐受性的诱导改善了IL-17诱导的T细胞RANKL表达。我们还发现,CIA - T细胞可增强破骨细胞生成,但口服耐受性 - T细胞则不然。从调节CII自身反应性的角度来看,口服耐受性可能是一种有前景的治疗选择,CII不仅可诱导CD4+ T细胞产生IL-17,还可诱导其表达RANKL。